Announcements Trials
Browse Landscape

Phase

Phase 1/2 5Phase 1 4

Status

Terminated 2Active not recruiting 2Completed 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 28Myelodysplastic Syndromes 13Leukemia 8Recurrence 6Melanoma 5Leukemia, Myelomonocytic, Chronic 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Blast Crisis 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Biphenotypic, Acute 2Thrombocytopenia 1Skin Neoplasms 1Sarcoma, Synovial 1Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden 1Prostatic Neoplasms 1Peripheral Blood Stem Cell Transplantation 1Neuroectodermal Tumors, Primitive 1Myeloproliferative Disorders 1Myeloid Malignancies 1Mesothelioma, Malignant 1Medulloblastoma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

pembrolizumab 74Nivolumab 53Ipilimumab 42Cyclophosphamide 32Interleukin-2 24aldesleukin 23Temozolomide 17fludarabine 16Biopsy 11trametinib 10fludarabine phosphate 10dabrafenib 10spartalizumab 8Paclitaxel 8Dacarbazine 8sargramostim 7cemiplimab 7binimetinib 7Cisplatin 7Bevacizumab 7poly ICLC 6lenvatinib 6epacadostat 6Radiotherapy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5encorafenib 5atezolizumab 5Vemurafenib 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Melanoma × Decitabine × Clear all
NCT05089370 2025-12-08

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

University of Colorado, Denver

Phase 1/2 Active not recruiting
8 enrolled
Dermatologic

Melanoma

NCT02650986 2025-06-17

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
15 enrolled 12 charts
DermatologicGynecologicSarcoma

Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT02608268 2023-12-06

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Novartis

Phase 1/2 Terminated
252 enrolled 67 charts
DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT00715793 2017-10-03

UPCI-07-008

University of Pittsburgh

Phase 1/2 Completed
39 enrolled 12 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT00925132 2017-07-02

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

University of Iowa

Phase 1/2 Terminated
39 enrolled 8 charts
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡